RS57875B1 - Kombinacija regorafeniba i acetilsalicilne kiseline za lečenje kolorektalnog kancera - Google Patents

Kombinacija regorafeniba i acetilsalicilne kiseline za lečenje kolorektalnog kancera

Info

Publication number
RS57875B1
RS57875B1 RS20181015A RSP20181015A RS57875B1 RS 57875 B1 RS57875 B1 RS 57875B1 RS 20181015 A RS20181015 A RS 20181015A RS P20181015 A RSP20181015 A RS P20181015A RS 57875 B1 RS57875 B1 RS 57875B1
Authority
RS
Serbia
Prior art keywords
acid
regorafenib
limited
colorectal cancer
acetylsalicylic acid
Prior art date
Application number
RS20181015A
Other languages
English (en)
Serbian (sr)
Inventor
Olaf Weber
Karl Ziegelbauer
Original Assignee
Bayer Pharma AG
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS57875(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG, Bayer Ag filed Critical Bayer Pharma AG
Publication of RS57875B1 publication Critical patent/RS57875B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20181015A 2012-09-25 2013-09-23 Kombinacija regorafeniba i acetilsalicilne kiseline za lečenje kolorektalnog kancera RS57875B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12185852 2012-09-25
PCT/EP2013/069735 WO2014048881A1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer
EP13770659.4A EP2900269B1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating colorectal cancer

Publications (1)

Publication Number Publication Date
RS57875B1 true RS57875B1 (sr) 2018-12-31

Family

ID=46963566

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20181015A RS57875B1 (sr) 2012-09-25 2013-09-23 Kombinacija regorafeniba i acetilsalicilne kiseline za lečenje kolorektalnog kancera

Country Status (29)

Country Link
US (1) US10898500B2 (enExample)
EP (1) EP2900269B1 (enExample)
JP (1) JP6294888B2 (enExample)
KR (1) KR102210575B1 (enExample)
CN (1) CN104994876A (enExample)
AU (1) AU2013322854B2 (enExample)
BR (1) BR112015006686B1 (enExample)
CA (1) CA2885688C (enExample)
CL (1) CL2015000744A1 (enExample)
CY (1) CY1120939T1 (enExample)
DK (1) DK2900269T3 (enExample)
EA (1) EA032023B1 (enExample)
ES (1) ES2687985T3 (enExample)
HK (1) HK1214169A1 (enExample)
HR (1) HRP20181462T1 (enExample)
HU (1) HUE039878T2 (enExample)
IL (1) IL237690B (enExample)
LT (1) LT2900269T (enExample)
MX (1) MX357035B (enExample)
MY (1) MY183969A (enExample)
NZ (1) NZ705860A (enExample)
PH (1) PH12015500587A1 (enExample)
PL (1) PL2900269T3 (enExample)
PT (1) PT2900269T (enExample)
RS (1) RS57875B1 (enExample)
SG (2) SG10201702356VA (enExample)
SI (1) SI2900269T1 (enExample)
WO (1) WO2014048881A1 (enExample)
ZA (1) ZA201502840B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
PL2900669T3 (pl) 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
AU2014356583B2 (en) 2013-11-26 2019-02-28 F. Hoffmann-La Roche Ag New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
CN104829523B (zh) * 2014-04-30 2017-10-31 药源药物化学(上海)有限公司 瑞戈非尼盐及其晶型、制备方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
BR112018006080A2 (pt) 2015-09-24 2018-10-09 F. Hoffmann-La Roche Ag novos compostos bicíclicos como inibidores de dupla ação de atx/ca
AU2016328437A1 (en) 2015-09-24 2018-01-25 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
WO2017050747A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
LT3474858T (lt) * 2016-06-28 2021-12-27 Asamedic As Dviejų komponentų kompozicija, apimanti acetilsalicilo rūgštį
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
PT3630112T (pt) * 2017-06-02 2024-04-23 Bayer Healthcare Llc Combinação de regorafenib e nivolumab para tratamento de cancro
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002014A1 (en) * 1999-07-02 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions for treating colorectal cancer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
JP2009514921A (ja) * 2005-11-10 2009-04-09 バイエル・ヘルスケア・アクチェンゲゼルシャフト 糖尿病性神経障害を処置するためのジアリールウレア
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB201002530D0 (en) * 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Also Published As

Publication number Publication date
HK1214169A1 (zh) 2016-07-22
EP2900269A1 (en) 2015-08-05
US20150202214A1 (en) 2015-07-23
AU2013322854A1 (en) 2015-04-02
PH12015500587A1 (en) 2015-05-11
HUE039878T2 (hu) 2019-02-28
KR102210575B1 (ko) 2021-02-02
WO2014048881A1 (en) 2014-04-03
ZA201502840B (en) 2017-11-29
MY183969A (en) 2021-03-17
EP2900269B1 (en) 2018-08-01
US10898500B2 (en) 2021-01-26
BR112015006686A2 (pt) 2019-08-27
AU2013322854B2 (en) 2018-07-19
CL2015000744A1 (es) 2016-01-08
SI2900269T1 (sl) 2018-10-30
CY1120939T1 (el) 2019-12-11
MX2015003728A (es) 2015-09-23
IL237690A0 (en) 2015-05-31
PL2900269T3 (pl) 2019-02-28
CA2885688C (en) 2021-03-02
CA2885688A1 (en) 2014-04-03
ES2687985T3 (es) 2018-10-30
HRP20181462T1 (hr) 2018-11-02
JP6294888B2 (ja) 2018-03-14
SG11201501963RA (en) 2015-04-29
SG10201702356VA (en) 2017-04-27
CN104994876A (zh) 2015-10-21
DK2900269T3 (en) 2018-10-01
KR20150060869A (ko) 2015-06-03
BR112015006686B1 (pt) 2022-04-05
MX357035B (es) 2018-06-25
JP2015529234A (ja) 2015-10-05
EA201500365A1 (ru) 2015-08-31
EA032023B1 (ru) 2019-03-29
PT2900269T (pt) 2018-10-22
LT2900269T (lt) 2018-11-12
NZ705860A (en) 2018-07-27
IL237690B (en) 2019-07-31

Similar Documents

Publication Publication Date Title
US10898500B2 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
US20220133888A1 (en) Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
WO2021160708A1 (en) Combination of regorafenib and msln-ttc for treating cancer
RU2774838C2 (ru) Комбинация регорафениба и ингибиторов pd-1/pd-l1(2) для лечения рака
BR122025015903A2 (pt) Combinação de regorafenib e inibidores de pd-1/pd-l1(2), seu uso, e kit para tratamento de distúrbios hiperproliferativos